BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/31/2021 6:51:26 AM | Browse: 596 | Download: 1720
 |
Received |
|
2021-02-02 05:04 |
|
Peer-Review Started |
|
2021-02-02 05:16 |
|
First Decision by Editorial Office Director |
|
2021-05-11 21:21 |
|
Return for Revision |
|
2021-05-11 21:21 |
|
Revised |
|
2021-05-24 03:12 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-19 03:12 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-19 04:50 |
|
Articles in Press |
|
2021-07-19 04:50 |
|
Edit the Manuscript by Language Editor |
|
2021-07-29 11:21 |
|
Typeset the Manuscript |
|
2021-08-25 08:30 |
|
Publish the Manuscript Online |
|
2021-08-31 06:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li Zhang, Jing Wang, Ling-Zhi Cui, Kai Wang, Ming-Ming Yuan, Rong-Rong Chen and Li-Jiao Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Li-Jiao Zhang, MM, Chief Physician, Professor, Department of Cadre Health, Shanxi Provincial Cancer Hospital, Employee Xincun No. 3, Xinghualing District, Taiyuan 030013, Shanxi Province, China. zljsx66@126.com |
| Key Words |
Non-small cell lung cancer; Next-generation sequencing; BRCA2 gene; Poly (adenosine diphosphate-ribose) polymerase inhibitor; Case report |
| Core Tip |
The clinical evidence for successful off-label use of targeted drugs for lung adenocarcinoma patients following progression on multiple lines of treatment is still lacking now. Herein, we describe the identification of a germline BRCA2 mutation in a lung adenocarcinoma patient. The patient had multiple refractory brain metastases and received olaparib combined with gefitinib and recombinant human endostatin following progression on multiple lines of treatment, with a progression-free survival of 13.5 mo. This case provides unequivocal clinical evidence for the off-label use of olaparib in lung adenocarcinoma patients with a BRCA mutation after disease progression. |
| Publish Date |
2021-08-31 06:51 |
| Citation |
Zhang L, Wang J, Cui LZ, Wang K, Yuan MM, Chen RR, Zhang LJ. Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report. World J Clin Cases 2021; 9(25): 7498-7503 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i25/7498.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i25.7498 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
